secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2026-05-12T20:07:17+00:00
Accession:  0001528287-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q1 RNS rev $21.7M (+19.5%); raises FY26 rev guidance to $99-101M
--------------------------------------------------------------------------

- RNS System revenue $21.7M (+19.5% YoY); total revenue $22.1M including $0.1M DIXI Medical.
- GAAP net loss $6.7M; Adjusted EBITDA loss ex DIXI improved to $3.3M from $4.1M YoY.
- Cash $54.8M vs $61.2M prior quarter; long-term debt $59M.
- FY2026 revenue guidance raised to $99-101M (from $98-100M), representing 21-23% RNS growth.
- Expects IGE indication expansion contribution after potential NAUTILUS PMA-S approval mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/0001528287-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/neuropace-8xkq12026earning.htm
  HTML page:      https://secwatch.observer/filing/0001528287-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer